Heart Rate Control With I<sub>f</sub> Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure　– A Randomized, Double-Blind, Placebo-Controlled Phase II Study –

DOI Web Site Web Site PubMed 10 Citations 27 References

Bibliographic Information

Other Title
  • Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure : A Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Study

Search this article

Abstract

Background:Elevated heart rate (HR) is an independent risk factor for cardiovascular outcomes in various cardiac diseases, including heart failure (HF).Methods and Results:Randomized placebo-controlled study was conducted to evaluate the effects of ivabradine, an Ifinhibitor, on the resting HR in 126 Japanese symptomatic HF patients with left ventricular ejection fraction ≤35%, resting HR ≥75 beats/min in sinus rhythm, and stable, optimal background treatment. Patients were randomly allocated into 3 groups: placebo; starting dose of ivabradine 2.5 mg twice daily (BID; 2.5 mg group); 5 mg BID group. The dose was increased up to 7.5 mg BID according to dose-adjustment criteria. After the 6-week treatment, the reductions in resting HR were significant in both the 2.5-mg (16.6±8.1 beats/min) and 5-mg (16.4±9.6 beats/min) groups (P<0.0001 for both groups) compared with placebo (1.7±8.7 beats/min). The most frequent side effect of ivabradine was phosphenes, but all were mild. Treatment was discontinued in 1 patient due to HF in the 5 mg group.Conclusions:Ivabradine starting at 2.5 or 5 mg BID effectively reduced resting HR in Japanese HF patients. Ivabradine at the starting dose of 2.5 mg BID could be safer than 5 mg BID. (Circ J 2016; 80: 668–676)

Journal

  • Circulation Journal

    Circulation Journal 80 (3), 668-676, 2016

    The Japanese Circulation Society

Citations (10)*help

See more

References(27)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top